Management of Anxiety in COPD Patients

First-Line Approach: Optimize COPD Management

The American Thoracic Society recommends assessing for hypoxemia first and providing supplemental oxygen if documented, targeting saturation 90-93%, as this prevents cognitive dysfunction from disordered gas exchange 1, 2
Optimize bronchodilator therapy with short-acting beta-agonists and consider adding ipratropium for persistent symptoms, as combination therapy is superior 2
Screen for depression and anxiety using validated tools like the Hospital Anxiety and Depression Questionnaire, as up to 40% of COPD patients have comorbid anxiety or depression 1, 2

The American College of Chest Physicians recommends buspirone as the safest and most effective anxiolytic for COPD patients because it does not cause respiratory depression 1, 2
Start with standard dosing and titrate upward as needed—buspirone is particularly effective when used in sufficiently high doses 1
If buspirone is insufficient or for patients with comorbid depression, the European Respiratory Society suggests SSRIs (sertraline or escitalopram) as the second-line choice, as they have better safety profiles than benzodiazepines in elderly COPD patients 3
Benzodiazepines are contraindicated in COPD patients due to increased all-cause mortality in severe COPD, plus additional morbidity including falls, delirium, CNS impairment, and respiratory depression 2, 3

The National Institute for Health and Care Excellence suggests pulmonary rehabilitation as the cornerstone treatment with Level A evidence for reducing both anxiety and dyspnea while improving exercise capacity and quality of life 1, 3, 2
A minimum duration of 6-12 weeks with twice-weekly supervised sessions of 2 hours each is recommended, as longer programs produce greater sustained benefits 3
Exercise programs must be maintained indefinitely, as benefits disappear rapidly upon discontinuation; encourage ongoing home-based exercise with periodic supervised sessions 3

Do not reflexively prescribe benzodiazepines for acute dyspnea in elderly COPD patients despite their common use—the risks far outweigh benefits 2, 3
Do not assume all breathlessness requires pharmacological intervention—non-pharmacological approaches are most appropriate for anxiety-driven dyspnea 3
Address the dyspnea-anxiety cycle: patients experience fear and anxiety in anticipation of dyspnea episodes, which creates heightened physiologic arousal that precipitates or exacerbates dyspnea 1, 3